What is NDC 51144-050?

51144-050 is the product NDC for Adcetris (brentuximab vedotin), Brentuximab vedotin 50 mg/10.5mL injection, powder, lyophilized, for solution, listed with the FDA by SEAGEN INC.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Adcetris (Brentuximab vedotin).

SEAGEN INC., NDC labeler code 51144. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Adcetris?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Adcetris NDC 51144-050 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)51144-050Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51144-0050Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51144-050-01	51144005001	1 VIAL, SINGLE-DOSE in 1 BOX (51144-050-01) / 10.5 mL in 1 VIAL, SINGLE-DOSEMarketed from Aug 25, 2011

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Adcetris
Generic name (nonproprietary): brentuximab vedotin
Active ingredients: Brentuximab vedotin — 50 mg/10.5mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: SEAGEN INC.NDC labeler code 51144
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125388
Marketing start: Aug 25, 2011
Listing expires: Dec 31, 2026
Other FDA classes: CD30-directed Antibody Interactions (Mechanism)Immunoconjugates (Chemical structure)Microtubule Inhibition (Physiologic effect)
Identifiers: Product ID 51144-050_a695c1a2-3acc-468b-a829-c8761dc041f6SPL ID a695c1a2-3acc-468b-a829-c8761dc041f6SPL set ID 3904f8dd-1aef-3490-e48f-bd55f32ed67fRxCUI 1147323, 1147327UNII 7XL5ISS668
Pharmacologic class: CD30-directed Immunoconjugate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451144005001 followed by a unit qualifier and the quantity

Package 51144-0050-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 11, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 51144-050

What is NDC 51144-050?: 51144-050 is the product NDC for Adcetris (brentuximab vedotin), Brentuximab vedotin 50 mg/10.5mL injection, powder, lyophilized, for solution, listed with the FDA by SEAGEN INC.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Adcetris (Brentuximab vedotin).
What is the active ingredient?: Brentuximab vedotin.
Who is the labeler?: SEAGEN INC., NDC labeler code 51144. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Adcetris?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Adcetris (Brentuximab vedotin) NDC 51144-050